Hydrocortisone in Severe Community-Acquired Pneumonia.
Pierre-François DequinFerhat MezianiJean-Pierre QuenotToufik KamelJean-Damien RicardJulio BadieJean ReignierNicholas HemingGaëtan PlantefèveBertrand SouweineGuillaume VoiriotGwenhaël ColinJean-Pierre FratJean-Paul MiraNicolas BarbarotBruno FrançoisGuillaume LouisSébastien GibotChristophe GuittonChristophe GiacardiSami HraiechSylvie VimeuxErwan L'HerHenri FaureJean-Etienne HerbrechtCamille BouisseAurélie JoretNicolas TerziArnaud GacouinCharlotte QuentinMercé JourdainMarie LeclercCarine CoffreHélène BourgoinCéline LengelléCaroline Caille-FénérolBruno GiraudeauAmélie Le Gougenull nullPublished in: The New England journal of medicine (2023)
Among patients with severe community-acquired pneumonia being treated in the ICU, those who received hydrocortisone had a lower risk of death by day 28 than those who received placebo. (Funded by the French Ministry of Health; CAPE COD ClinicalTrials.gov number, NCT02517489.).
Keyphrases
- community acquired pneumonia
- early onset
- south africa
- public health
- healthcare
- septic shock
- intensive care unit
- mental health
- randomized controlled trial
- clinical trial
- health information
- mechanical ventilation
- drug induced
- double blind
- climate change
- phase iii
- health promotion
- newly diagnosed
- open label
- study protocol
- human health